VJOncology is committed to improving our service to you

ASCO 2020 | KEYNOTE-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer

VJOncology is committed to improving our service to you

Ursula Matulonis

Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the KEYNOTE-100 trial (NCT02674061) of pembrolizumab in advanced recurrent ovarian cancer patients. Importantly, no significant difference in response rate was found between heavily and less heavily pretreated patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter